The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Science from our Sisters

Science from our Sisters

December 1, 2007 • By Meagan White

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Early Success for New Postmenopausal Osteoporosis Treatment

Investigators at the Sahlgrenska Academy at Göteborg University in Gothenburg, Sweden, discovered a possible new method for treating the osteoporosis associated with postmenopausal RA.

You Might Also Like
  • Science From Our Sisters
  • Science from our Sisters
  • Science from our Sisters
Explore This Issue
December 2007

New treatments alternatives are important since hormone replacement therapy with estrogen—the standard osteoporosis treatment—has recently been shown to have significant side effects.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Investigators began with a well-studied model of post-menopausal RA in mice. They then used raloxifene, a selective estrogen receptor modulator (SERM), to stimulate estrogen-like action.

“Raloxifene has recently been shown to be more efficient than estrogen in preventing some changes occurring in bone after the ovariectomy of mice—representing premenopause in women,” says Caroline Jochems, MD, lead author of the study, published in Arthritis & Rheumatism (2007;56[10]:3261-3270).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After the disease developed in mice, investigators were able to decrease arthritic activity with the drug—as evidenced by lower frequency of the disease and a lower severity score. They were also able to preserve bone architecture.

According to Dr. Jochems, “the method by which raloxifene prevents the progress of arthritis is not fully understood and needs to be further studied. It does not seem to have common anti-inflammatory properties in all conditions, but has been shown to have these effects in arthritis and autoimmune encephalitis.” Raloxifene prevents the progression of osteoporosis by slowing bone turnover; raloxifene increases bone formation and decreases bone resorption.

Dr. Jochems and colleagues were surprised to learn of raloxifene’s very potent anti-arthritic effects; the SERM does not have a subduing effect on disease in mice—known as delayed type hypersensitivity (DTH)—that is used as a simplified model for arthritis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Plans for clinical trials in humans are being discussed.

Knee Adduction May Be Key to Pain in OA

People with knee osteoarthritis (OA) typically have radiographic evidence, but the reverse is not always true; some patients who undergo radiographic screening positive for knee OA have no symptoms.

Now, researchers have discovered a biomechanical reason for the discrepancy: people who experience pain have significantly higher knee adduction moments. “The higher the knee adduction moment, the more likely one is to progress from mild to moderate to severe forms of the disease,” says Markus Wimmer, PhD, co-author of the study published in Arthritis Care & Research (2007;57[7]:1254-1260).

To understand why people with suspicious radiographs weren’t registering pain, investigators studied the gaits of asymptomatic adults with radiographs indicating mild degeneration at the knee. These people walked in the same manner as people with healthy radiographs. More revealing was the discovery that they had significantly lower knee adduction moments than people with painful symptoms.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Osteoarthritis, Research Reviews, Rheumatoid Arthritis Tagged With: A&R, AC&R, Hormone Therapy, Knee Osteoarthritis (OA), Osteoporosis, Postmenopausal hormone therapy, Rheumatoid Arthritis (RA), X-rayIssue: December 2007

You Might Also Like:
  • Science From Our Sisters
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)